LP-108 is under clinical development by Newave Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-108’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LP-108 overview

LP-108 is under development for the treatment of relapsed and refractory chronic lymphocytic leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia, acute myeloid leukemia (AML), Waldenstrom macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and diffuse large B-cell lymphoma. It is administered by oral route. It acts by targeting B cell lymphoma 2 (Bcl 2).

For a complete picture of LP-108’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.